In one breath
Merck’s filed revenue is growing and its newest drugs are landing approvals, but two enormous acquisition charges have swallowed the headline profit number this year. The stock is priced below its own historical median earnings multiple, meaning the market is paying less per dollar of Merck’s earnings than it typically has. The open question is whether the pipeline being assembled right now is wide enough to fill the gap when Keytruda, the drug that built the last decade, starts losing patent protection.
The moment that framed the call
JPMorgan analyst Christopher Schott put the sharpest question of Merck’s August 4, 2026 earnings call in plain terms: what does the earnings profile actually look like through the Keytruda loss-of-exclusivity period? Loss of exclusivity, or LOE, is the moment a branded drug’s patent protection expires and cheaper copies flood the market, often cutting revenue by half or more within a year or two. For Merck, Keytruda is not just a product. It is the engine. In the second quarter of 2026, Keytruda contributed $8.4 billion of the company’s $16.6 billion in total worldwide sales, meaning one drug accounts for roughly half of everything Merck sells.
CEO Rob Davis answered Schott directly: the LOE would be “more of a hill than a cliff,” with expectations for “a shallow dip with a fast return back to growth.” That is a claim worth testing against what the filings actually show, because the math and the mood, the gap between what filed fundamentals justify and what the market is currently paying, both hinge on whether that hill metaphor holds.
Where this moment sits in the filed history
Merck has changed meaningfully over the past several years. As recently as 2023, the 10-K for fiscal year 2023 shows net margin collapsing to under one percent, the result of a massive write-down that year. The following year, the 10-K for fiscal year 2024 shows revenue of $64.2 billion and net margin recovering to nearly twenty-seven percent. The 10-K for fiscal year 2025 shows revenue climbing further and margin improving again. That is a business that has been quietly improving its profitability per dollar of sales, even as revenue growth has slowed to a pace roughly matching the broader economy.
Then came 2026, and the acquisition spree. Merck recorded a charge of roughly nine billion dollars related to the Cidara acquisition in the first quarter, and a further charge of nearly six billion dollars tied to the Terns Pharmaceuticals acquisition in the second quarter. Together those charges are larger than what Merck earns in a typical year. They explain why the company reported a GAAP net loss for Q2 2026 even as sales grew five percent year over year. The charges are real cash out the door, but they are also one-time events, not a sign that the underlying business is deteriorating. A household analogy: it is like a family reporting a terrible year financially because they paid a large down payment on a house, even though their salaries went up.
What the call said, and what the filings show
Davis told the call that Merck is “substantially stronger, more diversified, and better positioned for sustainable growth” than five years ago. The filed revenue trend offers partial support: sales have grown meaningfully over the past five years, and the company raised its full-year 2026 revenue guidance to between $66.3 billion and $67.3 billion, up from its prior range. The MarketScreener report on Q2 2026 results confirms the revenue beat, with quarterly sales exceeding average analyst estimates by a comfortable margin.
The diversification claim is harder to verify from a single quarter. Animal Health contributed a meaningful but modest share of Q2 2026 sales, and the new product launches, more than twenty collectively, generated $1.5 billion in Q2 2026 revenue according to Merck’s own pipeline milestone release. That is real, but it is still less than one-fifth of what Keytruda alone produced in the same quarter. The diversification story is being written, not yet filed.
The pipeline as collateral
The hill-not-cliff argument rests almost entirely on what Merck is building to replace Keytruda revenue. The most concrete recent evidence is the FDA approval of Lipfendra on July 16, 2026, the first once-daily oral PCSK9 inhibitor, a class of drugs that lower LDL cholesterol. Current injectable PCSK9 drugs require a shot every two to four weeks; a pill taken daily is a genuinely different patient experience, and BofA analyst Jason Gerberry asked on the call whether Lipfendra would convert existing injectable users or open up primary care entirely, a question Merck did not answer with filed numbers.
In HIV, the FDA approved IDVYNSO in 2026, and Gurufocus reported positive Phase 3 results for a once-weekly islatravir/lenacapavir regimen announced in early August 2026, in collaboration with Gilead. In oncology, Phase 3 data for sacituzumab tirumotecan in endometrial cancer and tulisokibart in ulcerative colitis both came in positive during the quarter. Scotiabank analyst Louise Chen, as reported by Zacks, argued that Merck’s outlook “is becoming clearer ahead of Keytruda’s biosimilar competition, with more than $70 billion in potential sales from its products by the mid-2030s.” That figure is Chen’s projection, not a filed number, and BullScope cannot verify it independently from the dossier.
What the filings do show is the cost of building this pipeline. The 10-Q for the quarter ended March 31, 2026 shows total debt of $49.1 billion against a cash position that covers only a fraction of that load. Free cash flow for the trailing twelve months through March 2026 was $14.1 billion, meaning Merck generates enough cash each year to pay off roughly three-tenths of its debt, if it chose to stop investing. It is not choosing to stop investing.
Reading the numbers
- $16.6 billion in Q2 2026 sales. What it is: total worldwide revenue for the quarter ended June 30, 2026, per the MarketScreener earnings report. What it means here: 5% growth year over year, but Keytruda alone is half the total. Everyday version: imagine a bakery where one product, say sourdough, accounts for half of everything sold. The bakery is growing, but a sourdough problem is a bakery problem.
- P/E of 17.6 versus a decade median of 19.1. What it is: our data, computed from filed earnings and current price. A price-to-earnings multiple is the price tag per dollar of annual profit, so 17.6 means the market is paying $17.60 for each dollar Merck earns. What it means here: the market is paying less than its historical norm, sitting at the 38th percentile of its own decade range. Everyday version: a store that usually sells for $19 is marked down to $17.60. Whether that is a bargain depends entirely on whether the earnings hold.
- $49.1 billion in total debt as of March 31, 2026. What it is: per the 10-Q for the quarter ended March 31, 2026. What it means here: roughly three and a half times annual free cash flow, a leverage level that leaves limited room for error if a major pipeline drug fails. Everyday version: a household earning $14,000 a year carrying $49,000 in debt, manageable if income is stable, uncomfortable if it isn’t.
- $2.31 per share charge from the Terns acquisition. What it is: a one-time cost recorded in Q2 2026, per the earnings call transcript. What it means here: it explains almost the entire gap between the adjusted EPS guidance of roughly $2.71 and what the prior year’s trajectory would have suggested. Strip it out and the operating business looks different from the headline loss.
What the exchange leaves open
Schott’s question and Davis’s hill-not-cliff answer is the tension the market is currently pricing. The filed numbers show a business with improving margins, growing sales, and a pipeline producing real approvals. They also show a company spending aggressively, carrying significant debt, and still heavily dependent on a single drug whose exclusivity window is closing. Our data puts the current P/E below the decade median, meaning the market’s mood is more cautious than the historical average. Whether the math, the filed fundamentals, eventually closes that gap depends on whether the new drugs in the pipeline generate revenue at a pace that offsets what Keytruda will lose. That answer is not yet in any filing. It is still being written in clinical trials.
Sources
- MarketScreener: Merck Q2 2026 earnings results
- Seeking Alpha: Merck Q2 2026 earnings call transcript
- Seeking Alpha: Merck 2026 guidance update
- Gurufocus: Merck Q2 2026 call highlights
- Zacks: Merck Q2 earnings and guidance
- BioSpace: Lipfendra FDA approval
- Merck: pipeline milestone release
- SEC EDGAR: Merck 10-Q, quarter ended March 31, 2026
- SEC EDGAR: Merck 10-K, fiscal year ended December 31, 2025
- SEC EDGAR: Merck 10-K, fiscal year ended December 31, 2024
- SEC EDGAR: Merck 10-K, fiscal year ended December 31, 2023
